New pill aims to keep advanced breast cancer at bay
NCT ID NCT07321015
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study is testing fluzoparib, a daily pill, as a maintenance therapy for people with advanced triple-negative breast cancer whose disease was controlled by platinum chemotherapy. The trial will enroll 72 participants with or without BRCA gene mutations. The goal is to see how long the drug can delay cancer progression and how safe it is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fluzoparib (a PARP inhibitor taken as a capsule)
- What this could lead to
- If successful, fluzoparib could offer a new maintenance option to delay cancer progression in patients with advanced triple-negative breast cancer, especially those with BRCA mutations.
- What could go wrong
- This is a small, early-phase study (72 participants) with no comparison group, so results may not be definitive. Side effects like low blood counts are possible, and the drug may not work for everyone, particularly those without BRCA mutations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1/2 MUTATION OR NOT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers
- New combo attack on aggressive breast cancer brain tumors shows promise in early trial